Immunoassay Market to Reach US$ 47.5 Bn by 2031, Growing at 6% CAGR: New Report by Wissen Research

Wissen Research forecasts the global immunoassay market to expand from $35.5 billion in 2026 to $47.5 billion by 2031, a 6% CAGR, driven by rising disease prevalence, laboratory automation, biomarker testing, and decentralized point-of-care diagnostics. Multiplex and digital platforms are improving sensitivity and throughput, while Asia-Pacific is expected to post the fastest growth through 2030; North America remained the largest market in 2025. High equipment and consumables costs, assay interference, and cross-platform standardization gaps remain key adoption constraints.

Analysis

This is not a near-term earnings catalyst: the cited market outlook is a vendor-sponsored estimate and the projected growth rate is broadly consistent with mature diagnostics end-market growth. The investable issue is mix, not category growth. Installed-base leaders Roche (private), Siemens Healthineers (SHL), Abbott (ABT), Danaher (DHR) and Thermo Fisher (TMO) can convert automation placements into recurring reagent pull-through; recurring consumables support steadier gross margins, while analyzer placements initially pressure capital intensity and pricing.

The more consequential competitive risk is that multiplexing reduces tests-per-patient even as revenue per sample rises. That favors firms with differentiated assays, broad menus and closed ecosystems, but it can dilute commodity ELISA/research-kit suppliers unless they monetize higher-value panels. Bio-Rad (BIO) and Agilent (A) have greater exposure to research workflows where funding cycles and customer budget constraints matter; their upside requires evidence that clinical translation—not merely academic adoption—is accelerating.

Over the next 1-3 months, the actionable read-through is APAC order momentum and reagent organic growth disclosed in earnings, not market-research projections. QDEL's partnership-led menu expansion could improve international distribution, but it does not resolve the key valuation question: whether incremental placements generate durable instrument utilization rather than low-return channel inventory. Over 6-18 months, reimbursement for decentralized testing and cross-platform standardization are the swing factors; interoperability could weaken closed-platform pricing power, while reimbursement cuts would expose point-of-care economics.

Contrarian view: consensus may over-credit point-of-care as structurally disruptive to central labs. Hospitals optimize total cost per reported result, integration with chemistry workflows, quality controls and labor availability; this generally favors high-throughput incumbents unless decentralized assays demonstrate reimbursement-supported clinical utility. No broad sector trade is warranted on this release alone; use it as a diligence framework around upcoming guidance.

Key Decisions for Investors

• Maintain a quality bias toward ABT and SHL over QDEL for the next 6-12 months: favor companies with diversified diagnostic revenue and established service/reagent annuities. Reassess if diagnostics organic growth ex-COVID falls below management targets for two consecutive quarters or if reagent margins contract materially.
• Watch-list QDEL for a tactical long only after an earnings report shows both international VITROS placements and improving recurring consumables/utilization; require evidence of organic diagnostics growth and gross-margin stabilization. Without those data, partnership announcements are not a sufficient entry signal.
• Consider a 6-12 month pair, long SHL / short BIO, only if hospital automation order growth remains positive while research funding/order trends weaken. Thesis: integrated clinical-lab exposure captures labor-productivity spending, whereas research consumables face more discretionary budgets; exit if BIO reports sustained clinical-diagnostics acceleration or SHL's imaging/lab order book deteriorates.
• For DHR and TMO, treat any multiple expansion from diagnostic growth narratives as an opportunity to add only on pullbacks: immunoassays are too small relative to their portfolios to change consolidated earnings. Monitor bioprocess and instrument demand rather than this end-market forecast as the thesis-defining catalyst.